Replimune Group, Inc. (REPL)

Market Cap	412.92M
Revenue (ttm)	n/a
Net Income (ttm)	-280.22M
Shares Out	78.06M
EPS (ttm)	-3.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,856,132
Open	5.39
Previous Close	5.48
Day's Range	5.01 - 5.49
52-Week Range	2.68 - 17.00
Beta	0.67
Analysts	Buy
Price Target	8.25 (+55.96%)
Earnings Date	Aug 7, 2025

About REPL

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2018
• Employees: 479
• Stock Exchange: NASDAQ
• Ticker Symbol: REPL
• Website: https://www.replimune.com

Analyst Summary

According to 10 analysts, the average rating for REPL stock is "Buy." The 12-month stock price target is $8.25, which is an increase of 55.96% from the latest price.

Price Target

$8.25

(55.96% upside)

Analyst Consensus: Buy